Insights into the Prognostic Value of Small Nucleolar RNA U81 and SNORA7B in Breast Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Tsang JYS, Tse GM. Molecular classification of breast cancer. Adv Anat Pathol. 2020;27(1):27–35. doi:10.1097/PAP.0000000000000232
   PubMed Web of Science ®Google Scholar
• Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106. doi:10.1016/j.gendis.2018.05.001
   PubMed Web of Science ®Google Scholar
• Falaleeva M, Surface J, Shen M, de la Grange P, Stamm S. SNORD116 and SNORD115 change expression of multiple genes and modify each other’s activity. Gene. 2015;572(2):266–273. doi:10.1016/j.gene.2015.07.023
   PubMed Web of Science ®Google Scholar
• Chu L, Su MY, Maggi LB, et al. Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest. 2012;122(8):2793–2806. doi:10.1172/JCI63051
   PubMed Web of Science ®Google Scholar
• Liu Y, Ruan H, Li S, et al. The genetic and pharmacogenomic landscape of snoRNAs in human cancer. Mol Cancer. 2020;19(1):108. doi:10.1186/s12943-020-01228-z
   PubMed Web of Science ®Google Scholar
• Romano G, Veneziano D, Acunzo M, Croce CM. Small non-coding RNA and cancer. Carcinogenesis. 2017;38(5):485–491. doi:10.1093/carcin/bgx026
   PubMed Web of Science ®Google Scholar
• Liang J, Wen J, Huang Z, Chen X-P, Zhang B-X, Chu L. Small nucleolar RNAs: insight into their function in cancer. Front Oncol. 2019;9:587. doi:10.3389/fonc.2019.00587
   PubMed Web of Science ®Google Scholar
• Dsouza VL, Adiga D, Sriharikrishnaa S, Suresh PS, Chatterjee A, Kabekkodu SP. Small nucleolar RNA and its potential role in breast cancer - A comprehensive review. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188501. doi:10.1016/j.bbcan.2020.188501
   PubMed Web of Science ®Google Scholar
• Krishnan P, Ghosh S, Wang B, et al. Profiling of small nucleolar RNAs by next generation sequencing: potential new players for breast cancer prognosis. PLoS One. 2016;11(9):e0162622. doi:10.1371/journal.pone.0162622
   PubMed Web of Science ®Google Scholar
• Rubio M, Bustamante M, Hernandez-Ferrer C, et al. Circulating miRNAs, isomiRs and small RNA clusters in human plasma and breast milk. PLoS One. 2018;13(3):e0193527. doi:10.1371/journal.pone.0193527
   PubMed Web of Science ®Google Scholar
• Guo Y, Yu H, Wang J, et al. The landscape of small non-coding RNAs in triple-negative breast cancer. Genes (Basel). 2018;9(1):29. doi:10.3390/genes9010029
   PubMed Web of Science ®Google Scholar
• Schulten H-J, Bangash M, Karim S, et al. Comprehensive molecular biomarker identification in breast cancer brain metastases. J Transl Med. 2017;15(1):1–20. doi:10.1186/s12967-017-1370-x
   PubMed Web of Science ®Google Scholar
• Fang SX, Chen C, Guo Q, Ke XX, Lu HL, Xu G. High lncSNHG15 expression may predict poor cancer prognosis: a meta-analysis based on the PRISMA and the bio-informatics analysis. Biosci Rep. 2020;40(7):BSR20194468. doi:10.1042/BSR20194468
   PubMed Web of Science ®Google Scholar
• Gee H, Buffa F, Camps C, et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer. 2011;104(7):1168–1177. doi:10.1038/sj.bjc.6606076
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen E, Li Y, et al. H/ACA box small nucleolar RNA 7B acts as an oncogene and a potential prognostic biomarker in breast cancer. Cancer Cell Int. 2019;19(1):125. doi:10.1186/s12935-019-0830-1
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Meng Y, Yang Y, Zhang Y, Yang X, Li X, Hu C. The role of an immune signature for prognosis and immunotherapy response in endometrial cancer. Am J Transl Res. 2021;13(2):532–548.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Cui C, Liu Y, Gerloff D, et al. NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. Oncogene. 2021;40(5):909–921. doi:10.1038/s41388-020-01570-y
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu C, Gu D, et al. H/ACA box small nucleolar RNA 7A promotes the self-renewal of human umbilical cord mesenchymal stem cells. Stem Cells. 2017;35(1):222–235. doi:10.1002/stem.2490
   PubMed Web of Science ®Google Scholar
• Mattijssen S, Onnekink C, Pruijn G. The role of RNase MRP and RNase P in human ribosomal RNA synthesis. From a small RNA to a small man. 2010:79.
   Google Scholar
• Katz H, Alsharedi M. Immunotherapy in triple-negative breast cancer. Med Oncol. 2018;35(1):1–9. doi:10.1007/s12032-017-1071-6
   Web of Science ®Google Scholar
• Schmid P, Cortés J, Dent R, et al. KEYNOTE-522: phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Ann Oncol. 2019;30:v853–v854. doi:10.1093/annonc/mdz394.003
   PubMedGoogle Scholar
• Zhao S, Ma D, Xiao Y, et al. Molecular subtyping of triple‐negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist. 2020;25(10):e1481. doi:10.1634/theoncologist.2019-0982
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/JCI45014
   PubMed Web of Science ®Google Scholar
• Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020;6:54. doi:10.1038/s41523-020-00197-2
   PubMed Web of Science ®Google Scholar
• Chow RD, Chen S. Sno-derived RNAs are prevalent molecular markers of cancer immunity. Oncogene. 2018;37(50):6442–6462. doi:10.1038/s41388-018-0420-z
   PubMed Web of Science ®Google Scholar
• Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 2020;11:369. doi:10.3389/fimmu.2020.00369
   PubMed Web of Science ®Google Scholar
• Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):195–203. doi:10.1038/nri.2017.145
   PubMed Web of Science ®Google Scholar
• O’Brien N, Li R, Isaranuwatchai W, et al. How can we make better health decisions a Best Buy for all?: commentary based on discussions at iDSI roundtable on 2 (nd) May 2019 London, UK. Gates Open Res. 2019;3:1543. doi:10.12688/gatesopenres.13063.2
   PubMedGoogle Scholar
• Bouchard-Bourelle P, Desjardins-Henri C, Mathurin-St-Pierre D, et al. snoDB: an interactive database of human snoRNA sequences, abundance and interactions. Nucleic Acids Res. 2020;48(D1):D220–D225. doi:10.1093/nar/gkz884
   PubMed Web of Science ®Google Scholar